Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“upstream regulators of RB have been involved in cancer initiation in patients, both in familial and sporadic cases, and in several organs and tissues25–27.”
From Cellular mechanisms of tumour suppression by the retinoblastoma gene (2008) · cites this paper as [26]
Citations
Cites
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A
Mulligan, L. M., Kwok, J. B. J., Healey, C. S., Elsdon, M. J., Eng, C., Gardner, E., Love, D. R., Mole, S. E., Moore, J. K., Papi, L., et al. (1993) · Nature · doi:10.1038/363458a0 · Cited by 1,966
Sherr, C. J. (1993) · Cell · doi:10.1016/0092-8674(93)90636-5 · Cited by 1,960
pl5INK4B is a potentia| effector of TGF-β-induced cell cycle arrest
Hannon, G. J., & Beach, D. (1994) · Nature · doi:10.1038/371257a0 · Cited by 1,950
Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC
Donis-Keller, H., Dou, S., Chi, D., Carlson, K. M., Toshima, K., Lairmore, T. C., Howe, J. R., Moley, J. F., Goodfellow, P., & Wells, S. A. (1993) · Human Molecular Genetics · doi:10.1093/hmg/2.7.851 · Cited by 1,303
A p16 INK4a -Insensitive CDK4 Mutant Targeted by Cytolytic T Lymphocytes in a Human Melanoma
Wölfel, T., Hauer, M., Schneider, J., Serrano, M., Wölfel, C., Klehmann-Hieb, E., De Plaen, E., Hankeln, T., Meyer zum Büschenfelde, K.-H., & Beach, D. (1995) · Science · doi:10.1126/science.7652577 · Cited by 1,154
Hofstra, R. M. W., Landsvater, R. M., Ceccherini, I., Stulp, R. P., Stelwagen, T., Luo, Y., Pasini, B., Hoppener, J. W. M., van Amstel, H. K. P., Romeo, G., et al. (1994) · Nature · doi:10.1038/367375a0 · Cited by 1,149
Germline p16 mutations in familial melanoma
Hussussian, C. J., Struewing, J. P., Goldstein, A. M., Higgins, P. A. T., Ally, D. S., Sheahan, M. D., Clark, W. H., Tucker, M. A., & Dracopoli, N. C. (1994) · Nature Genetics · doi:10.1038/ng0994-15 · Cited by 977
Self-citationAnalysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus
Kamb, A., Shattuck-Eidens, D., Eeles, R., Liu, Q., Gruis, N. A., Ding, W., Hussey, C., Tran, T., Miki, Y., Weaver-Feldhaus, J., et al. (1994) · Nature Genetics · doi:10.1038/ng0994-22 · Cited by 855
Guan, K. L., Jenkins, C. W., Li, Y., Nichols, M. A., Wu, X., O'Keefe, C. L., Matera, A. G., & Xiong, Y. (1994) · Genes & Development · doi:10.1101/gad.8.24.2939 · Cited by 714
Research works printed but not linked: 1
- Walker, G.J. et al. .Mutations of the CDKN2/ p16INK4 gene in Australian melanoma kindreds. Hum. Molec. Genet. 4, 1845–1852 (1995).
Cited by
Items 201–300 of 817
A Comprehensive Review of Pediatric Tumors and Associated Cancer Predisposition Syndromes
Scollon, S., Anglin, A. K., Thomas, M. H., Turner, J. T., & Schneider, K. W. (2017) · Journal of Genetic Counseling · doi:10.1007/s10897-017-0077-8 · Cited by 76
“hereditary melanoma and pancreatic cancer syndrome, also described as familial atypical mole-malignant melanoma syndrome (Zuo et al. 1996).”
BackgroundDlugosz, A. A., Merlino, G. T., & Yuspa, S. H. (2002) · Journal of Investigative Dermatology Symposium Proceedings · doi:10.1046/j.1523-1747.2002.19631.x · Cited by 81
“…regulator in melanomagenesis, can be gleaned from the identi¢cation of germline mutations in two additional melanoma-prone kindreds of cyclin-dependent kinase 4 (CDK4), a promoter of cell cycle progression and a target of p16INK4a inhibition (Zuo et al, 1996; Russo et al, 1998; Sou¢r et al, 1998).”
BackgroundMolecular Diagnosis of Early Pancreatic Ductal Adenocarcinoma in High-Risk Patients
Wong, T., Howes, N., Threadgold, J., Smart, H. L., Lombard, M. G., Gilmore, I. T., Sutton, R., Greenhalf, W., Ellis, I., & Neoptolemos, J. P. (2001) · Pancreatology · doi:10.1159/000055852 · Cited by 71
Hereditary melanoma: Update on syndromes and management
Soura, E., Eliades, P. J., Shannon, K., Stratigos, A., & Tsao, H. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.08.037 · Cited by 93
Jen, M. V., Murphy, M. J., & Grant-Kels, J. M. (2009) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2008.09.011 · Cited by 69
Sporadic multiple primary melanoma cases: CDKN2A germline mutations with a founder effect
Auroy, S., Avril, M., Chompret, A., Pham, D., Goldstein, A. M., Bianchi‐Scarrà, G., Frébourg, T., Joly, P., Spatz, A., Rubino, C., et al. (2001) · Genes Chromosomes and Cancer · doi:10.1002/gcc.1183 · Cited by 72
“Two melanoma-predisposing genes have been identified to date, CDKN2A and CDK4 (Hussussian et al., 1994; Kamb et al., 1994a; Zuo et al., 1996).”
BackgroundSelf-citationVariants of the MATP/SLC45A2 gene are protective for melanoma in the French population
Guedj, M., Bourillon, A., Combadières, C., Rodero, M., Dieudé, P., Descamps, V., Dupin, N., Wolkenstein, P., Aegerter, P., Lebbe, C., et al. (2008) · Human Mutation · doi:10.1002/humu.20823 · Cited by 67
“Two highly penetrant melanomapredisposing genes have been identified to date, CDKN2A and CDK4, that are mainly involved in predisposition to familial melanoma and to multiple sporadic melanoma [Hussussian et al., 1994; Kamb et al., 1994; Zuo et al., 1996].”
BackgroundFamilial skin cancer syndromes
Ransohoff, K. J., Jaju, P., Tang, J. Y., Carbone, M., Leachman, S. A., & Sarin, K. Y. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.09.070 · Cited by 85
Rarity of CDK4 germline mutations in familial melanoma
Goldstein, A. M., Chidambaram, A., Halpern, A. C., Holly, E. A., Guerry, D., Sagebiel, R. W., Elder, D. E., & Tucker, M. A. (2002) · Melanoma Research · doi:10.1097/00008390-200202000-00008 · Cited by 67
Self-citationClinical germline genetic testing for melanoma.
Hansen, C. B., Wadge, L. M., Lowstuter, K. J., Boucher, K. M., & Leachman, S. A. (2004) · The Lancet Oncology · doi:10.1016/s1470-2045(04)01469-x · Cited by 66
Genetic epidemiology of melanoma
Ribero, S., Glass, D., & Bataille, V. (2016) · European Journal of Dermatology · doi:10.1684/ejd.2016.2787 · Cited by 64
BRAF as a melanoma susceptibility candidate gene?
Laud, K., Kannengiesser, C., Avril, M., Chompret, A., Stoppa‐Lyonnet, D., Desjardins, L., Eychène, A., Démenais, F., Lenoir, G., & Paillerets, B. B. (2003) · PubMed · Cited by 75
Management of familial melanoma
Newton‐Bishop, J., Harland, M., Randerson‐Moor, J. A., & Bishop, D. T. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)71010-5 · Cited by 79
Niehans, G. A., Kratzke, R. A., Froberg, M. K., Aeppli, D. M., Nguyen, P. L., & Geradts, J. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6990483 · Cited by 67
“…dysregulated the G1 checkpoint complex. example, mutations in CDK4 have been reported in melanoma lines and in familial melanoma kindreds; these mutations pre the CDK4–cyclin D1 complex from interacting with the inhibito p16INK4a protein (Bartkova et al, 1996; Zuo et al, 1996; Tsao e 1998).”
BackgroundTargets for molecular therapy of skin cancer
Green, C. L., & Khavari, P. A. (2004) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2003.11.007 · Cited by 64
Jiao, W., Datta, J., Lin, H., Dundr, M., & Rane, S. G. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605271200 · Cited by 70
Harland, M., Cust, A. E., Bádenas, C., Chang, Y., Holland, E. A., Aguilera, P., Aitken, J. F., Armstrong, B. K., Barrett, J. H., Carrera, C., et al. (2014) · Hereditary Cancer in Clinical Practice · doi:10.1186/1897-4287-12-20 · Cited by 63
“of the CDK4 gene, at the binding site for the CDKN2A gene product [4,5].”
BackgroundLoss of p16 expression is associated with histological features of melanoma invasion
Pavey, S. J., Cummings, M. C., Whiteman, D. C., Castellano, M., Walsh, M. D., Gabrielli, B. G., Green, A. C., & Hayward, N. K. (2002) · Melanoma Research · doi:10.1097/00008390-200212000-00003 · Cited by 66
Self-citationGenetic testing in hereditary melanoma
Tsao, H., & Niendorf, K. B. (2004) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2004.04.045 · Cited by 73
CDKN2A Germline Mutations in Individuals with Cutaneous Malignant Melanoma
Orlow, I., Begg, C. B., Cotignola, J., Roy, P., Hummer, A., Clas, B. A., Mujumdar, U., Canchola, R., Armstrong, B. K., Kricker, A., et al. (2007) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700689 · Cited by 74
“…type 2A; INK4a, inhibitor of cyclin-dependent kinase type 4; MPM, multiple primary melanoma; SPM, single primary melanoma Kamb et al., 1994): only six melanoma families harboring CDK4 mutations have been identified worldwide to date (Zuo et al., 1996; Soufir et al., 1998, Molven et al., 2005).”
BackgroundCell Cycle Regulation and Melanoma
Xu, W., & McArthur, G. A. (2016) · Current Oncology Reports · doi:10.1007/s11912-016-0524-y · Cited by 73
Jönsson, G. B., Bendahl, P., Sandberg, T., Kurbasic, A., Staaf, J., Sunde, L., Crüger, D. G., Ingvar, C., Olsson, H. L., & Borg, Å. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji280 · Cited by 62
Association Between INK4a-ARF and p53 Mutations in Skin Carcinomas of Xeroderma Pigmentosum Patients
Soufir, N., Daya-Grosjean, L., de La Salmonière, P., Moles, J. P., Dubertret, L., Sarasin, A., & Basset-Seguin, N. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.22.1841 · Cited by 73
Kadekaro, A. L. (2006) · Frontiers in Bioscience · doi:10.2741/1958 · Cited by 61
Development and progression of colorectal neoplasia
Manne, U., Shanmugam, C., Katkoori, V. R., Bumpers, H. L., & Grizzle, W. E. (2011) · Cancer Biomarkers · doi:10.3233/cbm-2011-0160 · Cited by 73
“In familial melanoma, there are germline mutations in the p16INK4a binding domain of CDK4 [342].”
Germline melanoma susceptibility and prognostic genes: A review of the literature
Ward, K. A., Lazovich, D., & Hordinsky, M. K. (2012) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2012.02.042 · Cited by 77
Chaudru, V., Laud, K., Avril, M.-F., Minière, A., Chompret, A., Bressac-de Paillerets, B., Demenais, F., & The French Familial Melanoma Study Group (2005) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-04-0777 · Cited by 61
“CDK4 acts as an oncogene and germline mutations of this gene have been found in only three melanoma-prone families worldwide (4, 8), whereas both CDK4 and CDKN2A mutations have been found to segregate in one Australian kindred (10).”
BackgroundMutation testing in melanoma families: INK4A, CDK4 and INK4D
Bishop, J. A. N., Harland, M., Bennett, D. C., Bataille, V, Goldstein, A. M., Tucker, M. A., Ponder, B. A. J., Cuzick, J., Selby, P., & Bishop, D. T. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690354 · Cited by 61
“Zuo et al (1996) have identified one such gene.”
BackgroundSelf-citationRuiz, A., Puig, S., Malvehy, J., Lázaro, C., Lynch, M., Giménez‐Arnau, A. M., Puig, L., Sánchez-Conejo, J., Estivill, X., & CASTEL, T. (1999) · Journal of Medical Genetics · doi:10.1136/jmg.36.6.490 · Cited by 66
p16INK4a‐induced senescence is disabled by melanoma‐associated mutations
Haferkamp, S., Becker, T. M., Scurr, L. L., Kefford, R. F., & Rizos, H. (2008) · Aging Cell · doi:10.1111/j.1474-9726.2008.00422.x · Cited by 59
“83, Neomarkers, Fremont, CA, USA).”
BackgroundPopulation-Based Prevalence of CDKN2A Mutations in Utah Melanoma Families
Eliason, M. J., Larson, A. A., Florell, S. R., Zone, J. J., Cannon‐Albright, L., Samlowski, W. E., & Leachman, S. A. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700094 · Cited by 63
Cyclins and cyclin-dependent kinases: from biology to tumorigenesis and therapeutic opportunities
Zabihi, M., Lotfi, R., Yousefi, A., & Bashash, D. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04135-6 · Cited by 67
Genetic and environmental factors in cutaneous malignant melanoma
Paillerets, B. B., Avril, M., Chompret, A., & Démenais, F. (2002) · Biochimie · doi:10.1016/s0300-9084(01)01360-8 · Cited by 60
Tormo, D., Ferrer, A., Bosch, P., Gaffal, E., Basner‐Tschakarjan, E., Wenzel, J., & Tüting, T. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0399 · Cited by 69
Cell cycle control of pancreatic beta cell proliferation
Rane, S. G. (2000) · Frontiers in bioscience · doi:10.2741/rane · Cited by 63
Cutaneous Melanoma in Childhood and Adolescence Shows Frequent Loss of INK4A and Gain of KIT
Daniotti, M., Ferrari, A., Frigerio, S., Casieri, P., Miselli, F., Zucca, E., Collini, P., Torre, G. D., Manoukian, S., Peissel, B., et al. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.422 · Cited by 63
“, 1994a); CDK4 exons 2-5-8 were amplified as described (Zuo et al., 1996).”
MethodEnhanced malignant tumorigenesis in Cdk4 transgenic mice
de Marval, P. L. M., Macias, E., Conti, C. J., & Rodríguez‐Puebla, M. L. (2003) · Oncogene · doi:10.1038/sj.onc.1207309 · Cited by 64
Platz, A., Ringborg, U. K., & Hansson, J. (2000) · Seminars in Cancer Biology · doi:10.1006/scbi.2000.0149 · Cited by 63
Genetics and genomics of melanoma
Ghosh, P., & Chin, L. (2009) · Expert Review of Dermatology · doi:10.1586/edm.09.2 · Cited by 74
Zhang, W., Zeng, Z., Zhou, Y., Xiong, W., Fan, S., Xiao, L., Huang, D., Li, Z., Li, D. C., Wu, M., et al. (2009) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmp025 · Cited by 59
Familial skin cancer syndromes
Jaju, P. D., Ransohoff, K. J., Tang, J. Y., & Sarin, K. Y. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.08.073 · Cited by 74
The Retinoblastoma Protein Is Required for Ras-Induced Oncogenic Transformation
Williams, J. P., Stewart, T. A., Li, B., Mulloy, R., Dimova, D. K., & Classon, M. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.4.1170-1182.2006 · Cited by 64
New developments in melanoma genetics
Hayward, N. K. (2000) · Current Oncology Reports · doi:10.1007/s11912-000-0022-z · Cited by 64
“Familial melanoma has proven to be a heterogeneous disease with the finding of rare (only three such families reported to date) mutations in the cyclindependent kinase 4 gene [1, 41 ].”
BackgroundSelf-citationCDKN2A mutations and MC1R variants in Italian patients with single or multiple primary melanoma
Pastorino, L., Bonelli, L. A., Ghiorzo, P., Queirolo, P., Battistuzzi, L., Balleari, E., Nasti, S., Gargiulo, S., Gliori, S., Savoia, P., et al. (2008) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2008.00512.x · Cited by 65
“We found no CDK4 mutation carrier in our study pop- ulation; this finding is not surprising as germline muta- tions of CDK4 have been detected in few cases worldwide (Majore et al., 2008; Molven et al., 2005; Pja- nova et al., 2007; Soufir et al., 1998, 2007; Zuo et al., 1996).”
BackgroundFriedman, R. J., Farber, M. J., Warycha, M. A., Papathasis, N., Miller, M. K., & Heilman, E. R. (2008) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2008.09.008 · Cited by 79
Torre, G. D., Pasini, B., Frigerio, S., Donghi, R., Rovini, D., Delia, D., Peters, G., Huot, T. J. G., Bianchi‐Scarrà, G., Lantieri, F., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1991 · Cited by 65
“Activating mutations of the CDK4 gene are rare in the development of familial (Zuo et al, 1996; Soufir et al, 1998) or sporadic melanoma (Wolfel et al, 1995; Guldberg et al, 1997).”
BackgroundMethodcdk6 Can Shorten G1 Phase Dependent upon the N-terminal INK4 Interaction Domain
Grossel, M. J., Baker, G. L., & Hinds, P. W. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.42.29960 · Cited by 56
Lou, J., Cao, W., Bernardin, F., Ayyanathan, K., Rauscher, F. J., & Friedman, A. D. (2000) · Oncogene · doi:10.1038/sj.onc.1203588 · Cited by 60
“This variant does not interact with p16INK4a (Zuo et al., 1996).”
BackgroundSchreiber, K., Rowley, D. A., Riethmüller, G., & Schreiber, H. W. (2006) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2006.03.001 · Cited by 59
“In addition, these studies revealed that many of these antigenic mutant proteins seem to play a functional role in causing or supporting the malignant behavior of the cancer cells [11–15].”
BackgroundRb/E2F: A two-edged sword in the melanocytic system
Halaban, R. (2005) · Cancer and Metastasis Reviews · doi:10.1007/s10555-005-1582-z · Cited by 61
“A mirror-image germ line point mutation in CDK4 (a substitution of arginine at position 24 to cysteine, R24C) that abolish the ability of the protein to bind p16INK4A and lead to increased CDK4 kinase activity was also found, but so far only in three melanoma families [85,96,97].”
BackgroundOmura‐Minamisawa, M., Diccianni, M. B., Chang, R. C., Batova, A., Bridgeman, L. J., Schiff, J., Cohn, S. L., London, W. B., & Yu, A. L.-T. (2001) · PubMed · Cited by 59
The therapeutic potential of targeting the cell cycle
Webster, K. R. (1998) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.7.6.865 · Cited by 60
Genetic Analysis of Mammalian Cyclin-Dependent Kinases and Their Inhibitors
Malumbres, M., Ortega, S., & Barbacid, M. (2000) · Biological Chemistry · doi:10.1515/bc.2000.105 · Cited by 55
“This mutation was first identified in patients with familial melanoma indicating that constitutive activation of Cdk4 may lead to tumor development (Wolfel et al., 1995; Zuo et al., 1996).”
BackgroundBocker, T., Rüschoff, J., & Fishel, R. A. (1999) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(99)00008-6 · Cited by 55
Melanoma: Clinical Features and Genomic Insights
Hawryluk, E. B., & Tsao, H. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a015388 · Cited by 72
“….p er sp ec ti ve si n m ed ic in e. o rg The cyclin-dependent kinase 4 (CDK4) gene locus encodes an enzyme that is inhibited by binding of p16 and is also found to be mutated among clusters of melanoma families (Zuo et al. 1996), although CDK4 mutations are more rare than CDKN2A gene mutations.”
BackgroundTormo, D., Ferrer, A., Gaffal, E., Wenzel, J., Basner‐Tschakarjan, E., Steitz, J., Heukamp, L. C., Gütgemann, I., Buettner, R., Malumbres, M., et al. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.060017 · Cited by 61
“This mutation acts as a dominant oncogene and was found in rare cases of both sporadic and hereditary melanoma.(10,11) Deregulated receptor tyrosine kinase signaling is another very important feature of human melanoma.”
BackgroundGRUBER, S. B., & ARMSTRONG, B. K. (2006) · Cancer Epidemiology and Prevention · doi:10.1093/acprof:oso/9780195149616.003.0063 · Cited by 52
Soufir, N., Paillerets, B. B., Desjardins, L., Lévy, C., Bombled, J., Gorin, I., Schlienger, P., & Stoppa‐Lyonnet, D. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.1005 · Cited by 53
Negative regulation of Fas-mediated apoptosis by FAP-1 in human cancer cells
Li, Y., Kanki, H., Hachiya, T., Ohyama, T., Irie, S., Tang, G.-L., Mukai, J., & Sato, T.-A. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20000815)87:4<473::aid-ijc3>3.0.co;2-1 · Cited by 52
Screening for CDKN2A Mutations in Hereditary Melanoma
Goldstein, A. M., & Tucker, M. A. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.10.676 · Cited by 57
Self-citationAberrant expression of G1/S regulators is a frequent event in sporadic pituitary adenomas
Simpson, D. J. W., Frost, S. J., Bicknell, J. E., Broome, J. C., McNicol, A. M., Clayton, R. N., & Farrell, W. E. (2001) · Carcinogenesis · doi:10.1093/carcin/22.8.1149 · Cited by 59
Genomic screen for genes involved in mammalian craniofacial development
Fowles, L. F., Bennetts, J. S., Berkman, J. L., Williams, E., Koopman, P., Teasdale, R. D., & Wicking, C. (2003) · genesis · doi:10.1002/gene.10165 · Cited by 52
“…syndrome type I (Pilia et al., 1996; Veugelers et al., 2000), cyclin-dependent kinase 4, which is involved in cases of familial melanoma (Zuo et al., 1996), and the cyclindependent kinase inhibitor p57Kip2, which has been implicated in Beckwith-Wiedemann syndrome (Caspary et al., 1999;…”
Tchernev, G., & Orfanos, C. E. (2007) · Journal of Cutaneous Pathology · doi:10.1111/j.1600-0560.2006.00700.x · Cited by 52
“Germline mutations that inactivate the p16 gene, a negative regulator of the G1-S checkpoint, or activate the positive regulator CDKs were found in about 25% of melanoma families.(3,4) This finding was confirmed by several groups and lead to the cloning and identification of the first melanoma susceptibility gene.”
BackgroundHigh- and low-penetrance cutaneous melanoma susceptibility genes
Fargnoli, M. C., Argenziano, G., Zalaudek, I., & Peris, K. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.5.657 · Cited by 62
Multiple primary cancers of the colon, breast and skin (melanoma) as models for polygenic cancers
Dong, C., & Hemminki, K. (2001) · International Journal of Cancer · doi:10.1002/ijc.1261 · Cited by 55
An update on the implications of cyclin D1 in melanomas
González‐Ruiz, L., González‐Moles, M. Á., González‐Ruiz, I., Ruiz‐Ávila, I., Ayén, Á., & Ramos‐García, P. (2020) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12874 · Cited by 49
“Other oncogenic alterations that can affect the tumor suppressor functions of CDKN2A/p16INK4 include CDK4 germinal line mutations (Soufir et al., 1998; Wölfel et al., 1995; Zuo et al., 1996), which are rare but can appear in familial and sporadic melanomas.”
BackgroundSpontaneous and UV Radiation–Induced Multiple Metastatic Melanomas in Cdk4R24C/R24C/TPras Mice
Hacker, E., Muller, H. K., Irwin, N., Gabrielli, B., Lincoln, D., Pavey, S., Powell, M. B., Malumbres, M., Barbacid, M., Hayward, N., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3196 · Cited by 51
“Underlining the importance of CDK4 in melanoma susceptibility are germ-line mutations (R24C or R24H) in some melanoma kindreds (5, 6 ) that render the protein resistant to INK4A inhibition.”
BackgroundInfluentialSelf-citationSkin Pigmentation Genetics for the Clinic
Ainger, S. A., Jagirdar, K., Lee, K., Soyer, H. P., & Sturm, R. A. (2017) · Dermatology · doi:10.1159/000468538 · Cited by 57
Melanoma Risk and Melanocyte Biology
Bertrand, J. U., Steingrímsson, E., Jouenne, F., Paillerets, B. B., & Larue, L. (2020) · Acta Dermato Venereologica · doi:10.2340/00015555-3494 · Cited by 63
“Mutations of CDK4 (cyclin-dependent kinase 4), encoding another cell cycle regulator, have also been linked to melanoma formation in families with phenotypes similar to those of families with CDKN2A mutations (28, 29).”
BackgroundCyclin-Dependent Kinase Inhibitors and Human Cancer
Kamb, A. (1998) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-71941-7_7 · Cited by 57
Is there a role for genetic testing in patients with melanoma?
Kefford, R. F., & Mann, G. J. (2003) · Current Opinion in Oncology · doi:10.1097/00001622-200303000-00007 · Cited by 51
Melanoma-Bearing Libechov Minipig (MeLiM): The Unique Swine Model of Hereditary Metastatic Melanoma
Horák, V., Palanova, A., Čížková, J., Miltrova, V., Vodička, P., & Skalníková, H. K. (2019) · Genes · doi:10.3390/genes10110915 · Cited by 67
“A CDK4 mutation was later found in two unrelated melanoma families [32], and the role of CDK4 mutations in melanoma development was confirmed [24].”
BackgroundA High-Throughput Panel for Identifying Clinically Relevant Mutation Profiles in Melanoma
Dutton-Regester, K., Irwin, D., Hunt, P., Aoude, L. G., Tembe, V., Pupo, G. M., Lanagan, C., Carter, C. D., O'Connor, L., O'Rourke, M., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0676 · Cited by 49
“Cyclin-dependent kinase 4 (CDK4) is an important kinase responsible for cell-cycle regulation and is a high penetrance melanoma predisposition gene mutated in a small number of families worldwide (45).”
BackgroundSelf-citationHansson, J. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-6448-9_13 · Cited by 61
Familial melanoma: a complex disorder leading to controversy on DNA testing
de Snoo, F. A., Bergman, W., & Gruis, N. A. (2003) · Familial Cancer · doi:10.1023/a:1025758527675 · Cited by 49
“Although CDKN2A has been identified as a melanoma susceptibility gene, for the majority of the families the cause of the melanoma syndrome remains unidentified (Figure 1). Candidate gene searches have led to the finding of a second melanoma susceptibility gene, CDK4 on chromosome 12q13 [ 58 ].”
A CDKN2A Mutation in Familial Melanoma that Abrogates Binding of p16INK4a to CDK4 but not CDK6
Jones, R., Ruas, M., Gregory, F., Moulin, S., Delia, D., Manoukian, S., Rowe, J., Brookes, S., & Peters, G. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1528 · Cited by 49
Fusenig, N. E., & Boukamp, P. (1998) · Molecular Carcinogenesis · doi:10.1002/(sici)1098-2744(199811)23:3<144::aid-mc3>3.0.co;2-u · Cited by 284
Jiao, W., Lin, H.-M., Datta, J., Braunschweig, T. A., Chung, J.-Y., Hewitt, S. M., & Rane, S. G. (2007) · Oncogene · doi:10.1038/sj.onc.1210970 · Cited by 56
“The importance of the CDK4 locus in human cancer was further emphasized upon identification of a germline CDK4-Arg24Cys (R24C) mutation in patients with familial melanoma that abolishes the ability of the mutant CDK4 kinase to interact with the p16 inhibitor (Wolfel et al., 1995; Zuo et al., 1996).”
BackgroundTwo-locus linkage analysis of cutaneous malignant melanoma/dysplastic nevi.
Goldstein, A. M., Goldin, L. R., Dracopoli, N. C., Clark, W. H., & Tucker, M. A. (1996) · PubMed · Cited by 51
Self-citationOmura‐Minamisawa, M., Diccianni, M. B., Batova, A., Chang, R. C., Bridgeman, L. J., Yu, A. L.-T., Pullen, J., Bowman, W. P., & Yu, A. L.-T. (2000) · PubMed · Cited by 54
Frost, S. J., Simpson, D. J. W., Clayton, R. N., & Farrell, W. E. (1999) · Molecular Endocrinology · doi:10.1210/me.13.11.1801 · Cited by 52
The paradox of senescent-marker positive cancer cells: challenges and opportunities
O’Sullivan, E. A., Wallis, R., Mossa, F., & Bishop, C. L. (2024) · npj Aging · doi:10.1038/s41514-024-00168-y · Cited by 62
“Germline mutations in p16 are seen in familial melanoma, preventing the binding of p16 to CDK4 and allowing foruncontrolledproliferation(reviewedinref.28).”
BackgroundPOLE mutations in families predisposed to cutaneous melanoma
Aoude, L. G., Heitzer, E., Johansson, P. A., Gartside, M. G., Wadt, K., Pritchard, A. L., Palmer, J. M., Symmons, J., Gerdes, A., Montgomery, G. W., et al. (2015) · Familial Cancer · doi:10.1007/s10689-015-9826-8 · Cited by 58
“Familial melanoma represents approximately 5–10 % of all cutaneous malignant melanoma (CMM) cases reported [1– 7].”
BackgroundSelf-citationClinical genetic testing for familial melanoma in Italy: A cooperative study
Bruno, W., Ghiorzo, P., Battistuzzi, L., Ascierto, P. A., Barile, M., Gargiulo, S., Gensini, F., Gliori, S., Guida, M., Lombardo, M., et al. (2009) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2009.03.039 · Cited by 52
Genetics of melanoma predisposition
Lin, J., Hocker, T. L. H., Singh, M., & Tsao, H. (2008) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2008.08682.x · Cited by 56
Effect of iron chelators on proliferation and iron uptake in hepatoma cells
Kicic, A., Chua, A. C. G., & Baker, E. (2001) · Cancer · doi:10.1002/1097-0142(20011215)92:12<3093::aid-cncr10107>3.0.co;2-b · Cited by 70
Kudoh, K., Ichikawa, Y., Yoshida, S., Hirai, M., Kikuchi, Y., Nagata, I., Miwa, M., & Uchida, K. (2002) · International Journal of Cancer · doi:10.1002/ijc.10331 · Cited by 52
“Histologic type Serous 19 3 (15) 4 (21) 4 (21) Mucinous 9 2 (20) 3 (33) 3 (33) Endometrioid 8 2 (25) 2 (25) 2 (25) Clear cell 8 1 (13) 6 (75) 6 (75) Undifferentiated 1 0 (0) 0 (0) 0 (0) p-value n.”
Melanoma Susceptibility Genes and Risk Assessment
Marzuka-Alcalá, A., Gabree, M., & Tsao, H. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-727-3_20 · Cited by 50
Current management of melanoma
Dunki-Jacobs, E. M., Callender, G. G., & McMasters, K. M. (2013) · Current Problems in Surgery · doi:10.1067/j.cpsurg.2013.04.001 · Cited by 53
Palmieri, G., Cossu, A., Ascierto, P. A., Botti, G., Strazzullo, M., Lissia, A., Colombino, M., Casula, M., Floris, C., Tanda, F., et al. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1513 · Cited by 49
“Conversely, in familial melanoma evidences strongly implicate p16/CDKN2A mutations in determining predisposition to the disease (Borg et al, 1996; SmithSorenson and Hoving, 1996; Zuo et al, 1996; Platz et al, 1997; Soufir et al, 1998).”
BackgroundCyclin‐dependent kinases: Masters of the eukaryotic universe
Pluta, A. J., Studniarek, C., Murphy, S., & Norbury, C. J. (2023) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1816 · Cited by 57
Risk and Survival of Cutaneous Melanoma Diagnosed Subsequent to a Previous Cancer
Yang, G. B., Barnholtz-Sloan, J., Chen, Y., & Bordeaux, J. S. (2011) · Archives of Dermatology · doi:10.1001/archdermatol.2011.1133 · Cited by 51
“cluding CDKN2A, CDK4, XP, and BRCA2, in the pathogenesis of melanoma.(9-15) In-”
BackgroundEricson, K. K., Krull, D., Slomiany, P., & Grossel, M. J. (2003) · PubMed · Cited by 46
Solar keratoses: A risk factor for melanoma but negative association with melanocytic naevi
Bataille, V. A., Sasieni, P. D., Grulich, A. E., Swerdlow, A. J., McCarthy, W. H., Hersey, P., Newton‐Bishop, J., & Cuzick, J. M. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980925)78:1<8::aid-ijc2>3.0.co;2-u · Cited by 83
Mitotic cyclins and cyclin-dependent kinases in melanocytic lesions
Tran, T., Ross, J. S., Carlson, J. A., & Mihm, M. C. (1998) · Human Pathology · doi:10.1016/s0046-8177(98)90418-x · Cited by 45
Cutaneous Malignancies: Melanoma and Nonmelanoma Types
Netscher, D. T. J., Leong, M., Orengo, I. F., Yang, D. J., Berg, C., & Krishnan, B. (2011) · Plastic & Reconstructive Surgery · doi:10.1097/prs.0b013e318206352b · Cited by 50
Höiom, V., Tuominen, R., Käller, M., Lindén, D., Ahmadian, A., Månsson‐Brahme, E., Egyházi, S., Sjöberg, K., Lundeberg, J., & Hansson, J. (2008) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2008.00526.x · Cited by 44
“…genes CDKN2A [MIM600160] (Berwick et al., 2006; Goldstein et al., 2007a; Hussussian et al., 1994; Kamb et al., 1994) and CDK4 [MIM123829] (Zuo et al., 1996), phenotype-asso- ciated variants of the melanocortin-1 receptor gene, MC1R [MIM155555], are associated with risk of CMM (Fargnoli…”
BackgroundCombining common genetic variants and non-genetic risk factors to predict risk of cutaneous melanoma
Gu, F., Chen, T.-H., Pfeiffer, R. M., Fargnoli, M. C., Calista, D., Ghiorzo, P., Peris, K., Puig, S., Menin, C., Nicolo, A. D., et al. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy282 · Cited by 49
Variants of the xeroderma pigmentosum variant gene (POLH) are associated with melanoma risk
Lucca, J. D., Guedj, M., Lacapère, J.-J., Fargnoli, M. C., Bourillon, A., Dieudé, P., Dupin, N., Wolkenstein, P., Aegerter, P., Saïag, P., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.04.034 · Cited by 47
Population‐based prevalence of CDKN2A and CDK4 mutations in patients with multiple primary melanomas
Helsing, P., Nymoen, D. A., Ariansen, S. L., Steine, S. J., Mæhle, L., Aamdal, S., Langmark, F., Loeb, M. E., Akslen, L. A., Molven, A., et al. (2007) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20518 · Cited by 55
“, 2005) and worldwide a total of eight such melanoma families have been reported (Zuo et al., 1996; Soufir et al., 1998, 2007; Molven et al., 2005; Pjanova et al., 2007).”
Background
Metadata
- Authors
- Zuo, L., Weger, J., Yang, Q., Goldstein, A. M., Tucker, M. A., Walker, G. J., Hayward, N., & Dracopoli, N. C.
- Affiliations
- National Institutes of Health (US)
- QIMR Berghofer Medical Research Institute (AU)
- Venue
- Nature Genetics
- Published
- 1996-01
- Volume
- 12
- Issue
- 1
- Pages
- 97-99
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2051506850
- Cited by
- 818
- References
- 29
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 11 · 2023: 13 · 2022: 13 · 2021: 19 · 2020: 19 · 2019: 23 · 2018: 24 · 2017: 36 · 2016: 24 · 2015: 27 · 2014: 32 · 2013: 30 · 2012: 19
- FWCI
- 14.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- CDK4, germline mutations, familial melanoma, cyclin-dependent kinases, cyclin D, retinoblastoma protein phosphorylation, G1 cell cycle checkpoint, hereditary melanoma, tumor-specific antigens
- MeSH terms
- Base Sequence, Carrier Proteins, Female, Humans, Male, Melanoma, Molecular Sequence Data, Pedigree, Proto-Oncogene Proteins, DNA Primers, Polymorphism, Single-Stranded Conformational, Cyclin-Dependent Kinases, Cyclin-Dependent Kinase Inhibitor p16, Cyclin-Dependent Kinase 4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.